- Home
- ADUR vs MCRB Comparison
ADUR vs MCRB Comparison
Compare ADUR & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUR
- MCRB
- Stock Information
- Founded
- ADUR 2011
- MCRB 2010
- Country
- ADUR Canada
- MCRB United States
- Employees
- ADUR N/A
- MCRB N/A
- Industry
- ADUR
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- ADUR
- MCRB Health Care
- Exchange
- ADUR NYSE
- MCRB Nasdaq
- Market Cap
- ADUR 144.2M
- MCRB 141.9M
- IPO Year
- ADUR N/A
- MCRB 2015
- Fundamental
- Price
- ADUR $5.13
- MCRB $0.68
- Analyst Decision
- ADUR Strong Buy
- MCRB Hold
- Analyst Count
- ADUR 1
- MCRB 5
- Target Price
- ADUR $50.00
- MCRB $4.00
- AVG Volume (30 Days)
- ADUR 48.4K
- MCRB 787.6K
- Earning Date
- ADUR 01-01-0001
- MCRB 03-13-2025
- Dividend Yield
- ADUR N/A
- MCRB N/A
- EPS Growth
- ADUR N/A
- MCRB N/A
- EPS
- ADUR N/A
- MCRB 0.00
- Revenue
- ADUR $213,431.00
- MCRB N/A
- Revenue This Year
- ADUR N/A
- MCRB N/A
- Revenue Next Year
- ADUR N/A
- MCRB N/A
- P/E Ratio
- ADUR N/A
- MCRB $874.10
- Revenue Growth
- ADUR 23.94
- MCRB N/A
- 52 Week Low
- ADUR $1.34
- MCRB $0.54
- 52 Week High
- ADUR $7.00
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- ADUR N/A
- MCRB 41.77
- Support Level
- ADUR N/A
- MCRB $0.67
- Resistance Level
- ADUR N/A
- MCRB $0.76
- Average True Range (ATR)
- ADUR 0.00
- MCRB 0.05
- MACD
- ADUR 0.00
- MCRB -0.00
- Stochastic Oscillator
- ADUR 0.00
- MCRB 22.89
About ADUR ADURO CLEAN TECHNOLOGIES INC
Aduro Clean Technologies Inc is a developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into feedstocks and higher-value fuels. The company's technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and costs.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.